Press release
Pharmacy OneSource Announces Free Webinar on Multi-drug Resistant Organism
Interventions to Prevent Acinetobacter baumannii in Healthcare SettingsBellevue, Wash. – Wolters Kluwer Health announced today that Pharmacy OneSource, software-as-a-service provider of Sentri7, an infection prevention surveillance, documentation and reporting application, is hosting a complimentary webinar with Jackie Whitaker, RN, MS, LHCRM, CIC, on "MDR Acinetobacter baumannii in the Short Term and Long Term Acute Care Setting."
Multi-drug resistant Acinetobacter baumannii is a health care-associated pathogen that can live for months in both a wet and dry environment. The high prevalence of this organism in the hospital environment results in colonization of the skin and respiratory tract. Mortality due to MDR Acinetobacter baumaunnii can run as high as 80%. Whitaker will review a study of interventions used to reduce the incidence of Acinetobacter baumannii infection and colonization. Interventions included 10% hypochlorite disinfection, hand hygiene, special contact isolation for suspected and confirmed cases, an educational tool for clinicians, patient and visitors, daily isolation rounds, automated report functions, and standardized nursing unit isolation practices.
MDR Acinetobacter baumannii in the Short Term and Long Term Acute Care Setting
DATE: August 3, 2011
TIME: 12:00 PM - 1:00 PM EST
WHERE: http://www.sentri7.com/infection
About the Presenter: Jackie Whitaker, RN, MS, LHCRM, CIC, has been an infection prevention and control specialist in the acute care setting for 20 years. An APIC member for 18 years, Jackie has also held a license in health care risk management since 2002. Actively involved in her local chapter Jackie has served as President, Secretary and been a member of the Nominating Committee.
Whitaker has extensive experience in project management and program design for a multitude of health care services, including, infection control, employee health, occupational health, infusion services, National Patient Safety Goals programs, etc. Through the utilization of technology and performance improvement tools, Whitaker and her team have effected excellent patient outcomes. She received 5 VHA awards for infection prevention projects to improve patient outcomes. Her interest in serving on the APIC Board of Directors is a result of her wanting to better serve her peers and the public in a broader capacity in infection prevention initiatives.
About Pharmacy OneSource
Pharmacy OneSource® is healthcare's #1 Software-as-a-Service (SaaS) provider. Our more than 100 innovative team members provide best-in-class, SaaS solutions to current and future challenges within health-systems worldwide. Our SaaS solutions contribute to swift and safe healthcare through earlier, easier and better access to data. More than 1,300 healthcare organizations worldwide utilize our HIPAA compliant web-based services.
Pharmacy OneSource is part of Wolters Kluwer Health, a leading global provider of information, business intelligence and point-of-care solutions for the healthcare industry. Wolters Kluwer Health is part of Wolters Kluwer, a market-leading global information services company with 2010 annual revenues of €3.6 billion ($4.7 billion).
Pharmacy OneSource
3535 Factoria Blvd. SE #440
Bellevue, WA 98006
This release was published on openPR.
Permanent link to this press release:
Copy
Please set a link in the press area of your homepage to this press release on openPR. openPR disclaims liability for any content contained in this release.
You can edit or delete your press release Pharmacy OneSource Announces Free Webinar on Multi-drug Resistant Organism here
News-ID: 184636 • Views: …
More Releases from Pharmacy OneSource
Richie's Specialty Pharmacy Selects Simplifi 797 for USP 797 Compliance
Wolters Kluwer Health, a leading global provider of information for healthcare professionals and students, announced today that Richie's Specialty Pharmacy, LLC has selected its Simplifi 797 software for achieving sterile compounding compliance.
Simplifi 797 is a web-based application that automates, integrates and streamlines quality activities and documentation related to U.S. Pharmacopeia's Chapter 797 guidelines. The software manages task scheduling for environmental monitoring and automates the reporting of exceptions and compliance.
"Simplifi…
Pharmacy OneSource® Partners with CriticalPoint™ to Offer the Next Generation …
Bellevue, Washington – Wolters Kluwer Health, a leading global provider of information for healthcare professionals and students, announced today that Pharmacy OneSource® has released a new version of Simplifi 797®, a web-based quality assurance software for USP chapter 797 compounding compliance.
The upgraded version of Simplifi 797 includes CriticalPoint's education program, which gives users unlimited access to 42 hours of ACPE-approved continuing education credits supporting compliance with USP Chapter . Lessons…
Wolters Kluwer Health Unveils Integration between UpToDate and Sentri7
Bellevue, WA -- Wolters Kluwer Health, a leading global provider of information for healthcare professionals and students, announced today that UpToDate's clinical knowledge system has been integrated with Sentri7 surveillance software by Pharmacy OneSource.
This partnership of evidence-based clinical information through UpToDate and clinical patient surveillance from Sentri7 offers healthcare providers actionable information at the point of care to make better decisions in directing patient care.
UpToDate synthesizes the most recent medical…
More Releases for Acinetobacter
Acinetobacter Pneumonia Therapeutics Market Revenue Report with Forecast to 2034
InsightAce Analytic Pvt. Ltd. announces the release of a market assessment report on the "Global Acinetobacter Pneumonia Therapeutics Market Size, Share & Trends Analysis Report By Drug Class (Cephalosporins, Carbapenems, Aminoglycosides, Polymyxins), By Route of Administration (Oral, Intravenous, Others), Region, Market Outlook And Industry Analysis 2034"
The global Acinetobacter Pneumonia Therapeutics Market Size is valued at USD 646.05 Mn in 2024 and is predicted to reach USD 1101.68 Mn by the…
Acinetobacter Pneumonia Therapeutics Market Combating a Resistant Threat Market …
Acinetobacter Pneumonia Therapeutics Market to reach over USD 927.1 Mn by the year 2031 - Exclusive Report by InsightAce Analytic
InsightAce Analytic Pvt. Ltd. announces the release of a market assessment report on the "Global Acinetobacter Pneumonia Therapeutics Market Size, Share & Trends Analysis Report By Drug Class (Cephalosporins, Carbapenems, Aminoglycosides, Polymyxins), By Route of Administration (Oral, Intravenous, Others), Region, Market Outlook And Industry Analysis 2031"
The global Acinetobacter Pneumonia Therapeutics Market…
Acinetobacter Pneumonia Therapeutics Market Report Explores Reviews Analysis Rep …
Acinetobacter Pneumonia Therapeutics Market is estimated to reach over USD 927.1 Mn by 2031, exhibiting a CAGR of 5.30% during the forecast period.
InsightAce Analytic Pvt. Ltd. announces the release of a market assessment report on the "Global Acinetobacter Pneumonia Therapeutics Market Size, Share & Trends Analysis Report By Drug Class (Cephalosporins, Carbapenems, Aminoglycosides, Polymyxins), By Route of Administration (Oral, Intravenous, Others), Region, Market Outlook And Industry Analysis 2031"
The global Acinetobacter…
Global Acinetobacter Infections Treatment Market Research Report 2020
LOS ANGELES - USA, Acinetobacter is a group of bacteria commonly found in soil and water. While there are many types or "species" of Acinetobacter and all can cause human disease, Acinetobacter baumannii accounts for about 80% of reported infections.
Outbreaks of Acinetobacter infections typically occur in intensive care units and healthcare settings housing very ill patients. Acinetobacter infections rarely occur outside of healthcare settings.
Acinetobacter is often resistant to many commonly…
Acinetobacter Infections Treatment Market with Worldwide Industry Analysis to 20 …
Global Acinetobacter Infections Treatment Market: Overview
Acinetobacter baumannii is a rod shaped gram-negative coccobacillus bacterium. This bacterium is becoming an important cause of hospital derived bacterial infection affecting people with weakened immune system. Acinetobacter infections usually affect organ systems, which have a high content of fluid (e.g. peritoneal fluid, respiratory tract, urinary tract, cerebrospinal fluid etc.) leading to infections related to continuous ambulatory peritoneal dialysis and nocosomial pneumonia. At present,…
Acinetobacter Infections - Pipeline Review, H1 2017 - Pharmaceutical Market Repo …
Global Markets Direct's latest Pharmaceutical and Healthcare disease pipeline guide Acinetobacter Infections - Pipeline Review, H1 2017, provides an overview of the Acinetobacter Infections (Infectious Disease) pipeline landscape.
Acinetobacter is a gram-negative coccobacillus. Acinetobacter infections are uncommon but, when they occur, usually involve organ systems that have a high fluid content (respiratory tract, CSF, peritoneal fluid, urinary tract). Symptoms include fever (high body temperature), red, swollen, warm or painful skin areas…